Latest | Instant Finance & Market News_第158页

07:52

[ KONTA CHINA (01312.HK): Wang Limin resigns as President but remains Chairman, Li Qingshan appointed Executive Director and President ] NewTimeSpace News: On 17 August 2026, KONTA CHINA (01312.HK) announced that Executive Director and Chairman Wang Limin has resigned as President due to internal work arrangements (remaining as Chairman), and Li Qingshan has been appointed Executive Director and President, as well as a member of the Executive Committee and the Share Trading Committee, effective 17 August 2026.

Tag： KONTA CHINA 01312.HK Appointment

07:40

[ CANBRIDGE-B (01228.HK): Maralixibat Oral Solution Approved for NHI Reimbursement in Taiwan, China, Effective 1 September ] NewTimeSpace News: On 18 August 2026, CANBRIDGE-B (01228.HK) announced that maralixibat oral solution has been approved by the National Health Insurance Administration of Taiwan, China for NHI coverage in treating both ALGS and PFIC, effective 1 September 2026. Maralixibat is the first approved drug for ALGS and PFIC in Taiwan, China, holding FDA Breakthrough Therapy designation and orphan drug designations across multiple jurisdictions. The company views the inclusion as an important milestone in its rare disease commercialization that will substantially reduce the financial burden on patient families.

Tag： CANBRIDGE-B 01228.HK R&D Progress

07:28

[ IMMUNOFOCO-B: Re-files HKEX Listing Application on August 18, Huatai International as Sole Sponsor, Core Product IMC002 in Phase III Registration Trial ] NewTimeSpace News: On 18 August 2026, Shenzhen Immunofoco Biotechnology Co., Ltd. (IMMUNOFOCO-B) re-filed its HKEX listing application with Huatai International as sole sponsor. Founded in 2020, the CAR-T cell therapy company's core product IMC002 (anti-CLDN18.2 CAR-T) is in a registration Phase III trial for advanced gastric cancer, with an IND submitted in June 2026 for first-line pancreatic cancer. The pipeline comprises eight additional candidates spanning both ex vivo and in vivo CAR-T platforms.

Tag： Immunofoco IPO file a listing application

21:54

[ MOISELLE INT'L (00130.HK): Independent Non-Executive Director Ng Lai Man Receives Summons from Magistrates' Court, Board Considers No Impact on Group Operations ] NewTimeSpace News: On 17 August 2026, MOISELLE INT'L (00130.HK) announced that independent non-executive director Ng Lai Man has received a personal summons from the Magistrates' Court under the Magistrates Ordinance, relating to another licensed corporation in which she serves as a director and unrelated to the group; after assessment, the board considers the case will have no impact on the group's operations and financial position, and Ms. Ng remains an independent non-executive director.

Tag： MOISELLE INTL Board Changes 00130.HK

21:52

[ TATAHEALTH (01255.HK): Former Independent Non-Executive Director Files Winding-Up Petition over HKD 139,150.68 Unpaid Director Remuneration, Hearing Set for 21 October ] NewTimeSpace News: On 17 August 2026, TATAHEALTH (01255.HK) issued an inside information announcement stating that former independent non-executive director Tao Zhiqiang had filed a winding-up petition against the company with the High Court of Hong Kong over unpaid director remuneration of HKD 139,150.68; no winding-up order has been made, and the hearing is scheduled for 21 October 2026. The board believes the matter can be resolved given the small claim amount, and the company is seeking legal advice and taking necessary measures.

Tag： TATAHEALTH 01255.HK Litigation winding-up petition

21:44

[ SINOPEC SSC(01033.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at CNY 758.34 million, YoY decrease of 0.24% ] August 17, 2026, SINOPEC SSC(01033.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at CNY 37.66 billion, increased by 1.66% YoY

Tag： SINOPEC SSC 01033.HK

21:44

[ AI ENERGY ENG (01751.HK) plans to conduct a rights issue on the basis of \"5 for 2\", with estimated net proceeds of HKD 72.4 million ] AI ENERGY ENG (01751.HK) plans to conduct a rights issue on the basis of \"5 for 2\", with estimated net proceeds of HKD 72.4 million.

Tag： AI ENERGY ENG 01751.HK

21:39

[ SINOPEC KANTONS (00934.HK): Terminates Original IT Framework Agreement and Enters into Digital Intelligence Information System Services Framework Agreement, Also Signs Equipment Maintenance Services Framework Agreement ] NewTimeSpace News: On 17 August 2026, SINOPEC KANTONS (00934.HK) announced the termination of the original IT project framework master agreement and the signing of a digital intelligence information system services framework agreement with Sinopec Yinko and the Shared Services Company (service term to end-2028, with an annual cap of RMB 15 million each year), while wholly-owned subsidiary Huade Petrochemical also signed an equipment maintenance services framework agreement with Sinopec Guangzhou Branch (annual caps of RMB 3.0-3.2 million); the transactions constitute continuing connected transactions, but are exempt from independent shareholders' approval and circular requirements.

Tag： SINOPEC KANTONS 00934.HK strategic cooperation

21:36

[ GOFIN TECH QUANT (00290.HK): Placing of 218.75 Million Existing Shares Completed, Top-up Subscription of New Shares Terminated ] NewTimeSpace News: On 17 August 2026, GOFIN TECH QUANT (00290.HK) announced that the placing was completed on 4 August, with an aggregate of 218.75 million existing shares placed at HKD 1.60 per share to not less than six placees; as the conditions precedent were not satisfied, the board decided not to proceed with the top-up subscription of new shares at this stage, and largest shareholder Dr. Liu Zhiwei holds approximately 24.78%.

Tag： GOFIN TECH QUANT 00290.HK Placing

21:33

[ GAUSH MEDITECH (02407.HK): Subsidiary Gaushi Innovation Reaches Five-Year Exclusive Distribution Cooperation with HEIDELBERG, Corneal Confocal Microscope T3 Goes Global ] NewTimeSpace News: On 17 August 2026, GAUSH MEDITECH (02407.HK) announced that its subsidiary Gaushi Innovation signed a five-year exclusive agency agreement with Germany's HEIDELBERG, under which HEIDELBERG will exclusively distribute the independently developed corneal confocal microscope T3 globally except China; the two parties have been important business partners since 1998.

Tag： GAUSH MEDITECH 02407.HK strategic cooperation

21:31

[ CC SECURITIES (01375.HK): Wholly-Owned Subsidiary and Others Sign Partnership Agreement to Establish RMB 104 Million Digital Equity Investment Fund, Constituting Connected Transaction ] NewTimeSpace News: On 17 August 2026, CC SECURITIES (01375.HK) announced that its wholly-owned subsidiary Zhongding Kaiyuan and three other parties signed a partnership agreement to establish the Henan Xiangding Digital Equity Investment Fund (Limited Partnership) with aggregate committed capital of RMB 104 million, targeting investment in a smart culture and tourism company; as Zhongyuan Jinxiang and Jinxiang Relay Fund are connected persons, the transactions constitute connected transactions, but are exempt from the circular and independent shareholders' approval requirements.

Tag： CC SECURITIES Fund Management 01375.HK

21:27

[ CHINAGOLDINTL (02099.HK): Engages SRK to Advance Independent NI 43-101 Feasibility Study for Changshanhao Underground Development, Pre-Development Works Commence ] NewTimeSpace News: On 17 August 2026, CHINAGOLDINTL (02099.HK) announced the engagement of SRK Consulting to conduct an independent feasibility study stage assessment of the proposed underground development project at the Changshanhao Gold Mine and prepare an NI 43-101 technical report, with block caving proposed for the transition from open-pit to underground mining and pre-development works already commenced; SRK's work will proceed in two stages of gap analysis and independent feasibility study.

Tag： CHINAGOLDINTL 02099.HK Research Progress

19:55

[ HKEX (00388.HK): Group Chief Executive Bonnie Y Chan's Contract Renewed for Three Years, Term to Run to February 2030 ] NewTimeSpace News: On 17 August 2026, HKEX (00388.HK) announced that the board has approved a three-year renewal of the contract of Group Chief Executive Bonnie Y Chan, from 1 March 2027 to 28 February 2030, with the reappointment approved by the Securities and Futures Commission; her remuneration package includes a basic annual salary of HKD 12 million plus discretionary bonuses and share awards.

Tag： HKEX 00388.HK Board Changes

19:54

[ HAIXI PHARMA (02637.HK): HX9428 for Neovascular Age-Related Macular Degeneration Granted Fast Track Designation by US FDA ] NewTimeSpace News: On 17 August 2026, HAIXI PHARMA (02637.HK) announced that its self-developed oral small-molecule innovative drug HX9428 has been granted Fast Track Designation by the US FDA for the treatment of neovascular age-related macular degeneration (nAMD); HX9428 has completed Phase I clinical studies, is advancing Phase II studies, and has received FDA approval to conduct a Phase II clinical trial in the United States.

Tag： HAIXI PHARMA 02637.HK Research Progress

19:42

[ HANXBIO-B(03378.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at loss of CNY 36.88 million, loss widened by 1.22% YoY ] August 17, 2026, HANXBIO-B(03378.HK) released its Interim Report for the period ended December 31, 2026

Tag： HANXBIO-B 03378.HK

19:42

[ BILLION IND(02299.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at CNY 985.32 million, YoY increase of 161.57% ] August 17, 2026, BILLION IND(02299.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at CNY 12.71 billion, increased by 34.03% YoY

Tag： BILLION IND 02299.HK

19:41

[ ZHIDA TECH(02650.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at loss of CNY 116.61 million, loss widened by 288.46% YoY ] August 17, 2026, ZHIDA TECH(02650.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at CNY 340.32 million, decreased by 13.33% YoY

Tag： ZHIDA TECH 02650.HK

19:41

[ STAR SPORTS MED(01609.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at CNY 27.4 million, YoY decrease of 26.12% ] August 17, 2026, STAR SPORTS MED(01609.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at CNY 163.43 million, increased by 21.62% YoY

Tag： STAR SPORTS MED 01609.HK

19:41

[ COWELL(01415.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at USD 89.87 million, YoY increase of 33.35% ] August 17, 2026, COWELL(01415.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at USD 1.6 billion, increased by 17.97% YoY

Tag： COWELL 01415.HK

19:41

[ CONANT OPTICAL(02276.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at CNY 301.18 million, YoY increase of 10.38% ] August 17, 2026, CONANT OPTICAL(02276.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at CNY 1.17 billion, increased by 7.64% YoY

Tag： CONANT OPTICAL 02276.HK